Federal investigators say that a Chinese drug manufacturer, previously on the Food and Drug Administration’s list of preapproved foreign companies allowed to import GLP-1 ingredients, was able to bring in batches of the weight loss drug from an unauthorized supplier and introduce the substance of unknown origin into the U.S. drug supply.
In September 2025, now-ousted FDA Commissioner Marty Makary launched a so-called “green list” of overseas facilities permitted to ship active pharmaceutical ingredients for GLP-1 medication into the United States. The list is meant to prevent “potentially dangerous GLP-1 (glucagon-like peptide-1) active pharmaceutical ingredients (APIs) from unverified foreign sources from entering the U.S. market.”
However, one of the greenlisted companies, Harbin Jixianglong Biotech Co., later received an infraction letter from the FDA determining that the…



